Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy

S Hong; J Valent; L Rybicki; D Abounader; B Bolwell; R Dean; A T Gerds; D Jagadeesh; B K Hamilton; B Hill; M E Kalaycio; B Pohlman; F Reu; C Samaras; R Sobecks; N S Majhail; H D Liu

doi:10.1038/bmt.2015.326

Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy

Bone Marrow Transplant. 2016 May;51(5):732-4. doi: 10.1038/bmt.2015.326. Epub 2016 Jan 4.

Authors

S Hong¹, J Valent², L Rybicki³, D Abounader⁴, B Bolwell^{2

4}, R Dean^{2

4}, A T Gerds^{2

4}, D Jagadeesh^{2

4}, B K Hamilton^{2

4}, B Hill^{2

4}, M E Kalaycio^{2

4}, B Pohlman^{2

4}, F Reu^{2

4}, C Samaras^{2

4}, R Sobecks^{2

4}, N S Majhail^{2

4}, H D Liu^{2

4}

Affiliations

¹ Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
² Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH, USA.
³ Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
⁴ Blood & Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

PMID: 26726941
DOI: 10.1038/bmt.2015.326

No abstract available

MeSH terms

Adult
Aged
Bortezomib / therapeutic use*
Female
Hematopoietic Stem Cell Transplantation*
Humans
Immunoglobulin Light-chain Amyloidosis / therapy*
Male
Middle Aged
Pyrazines / therapeutic use
Retrospective Studies
Transplantation, Autologous

Substances

Pyrazines
Bortezomib